Affinage

HOXA9

Homeobox protein Hox-A9 · UniProt P31269

Length
272 aa
Mass
30.2 kDa
Annotated
2026-06-10
100 papers in source corpus 42 papers cited in narrative 42 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

HOXA9 is a homeodomain transcription factor that governs hematopoietic and endothelial gene programs and is a central oncogenic driver in acute myeloid leukemia (PMID:9649441, PMID:15928198, PMID:19056693). It binds DNA cooperatively with the TALE cofactors PBX and MEIS1, forming trimeric complexes through its hexapeptide motif and paralog-specific homeodomain residues; MEIS1 enhances HOXA9-PBX assembly even in the absence of DNA (PMID:10082572, PMID:30952900), and a high-resolution HoxA9-Pbx1-DNA structure shows the posterior hexapeptide adopts an altered conformation conferring stronger affinity and altered specificity (PMID:12923056). Cofactor selection is functionally decisive: collaboration with MEIS1a transforms primary marrow cells whereas PBX1b does not (PMID:9649441), and PBX3 specifically is the critical cofactor for MLL-fusion leukemogenesis (PMID:23264595). As a pioneer factor at de novo enhancers, HOXA9 recruits C/EBPalpha and the MLL3/MLL4 H3K4-methyltransferase complex to establish leukemia-specific enhancers, and its genome-wide binding co-occurs with C/EBPalpha and STAT5 (PMID:24958854, PMID:30270123, PMID:29496663). Through these complexes it directly activates pro-survival and proliferative targets including Pim1 (which inactivates pro-apoptotic BAD), Bcl-2, Cdk6, CyclinD1, and a positive-feedback loop enforcing the complete HoxA locus (PMID:17327400, PMID:24177192, PMID:30463913), while co-repressing the Cdkn2a/b locus to overcome G1 arrest (PMID:24958854). HOXA9 activity is tuned post-translationally: PKC phosphorylates Ser204/Thr205 to reduce DNA binding (PMID:15082777), PRMT5 symmetrically dimethylates Arg140 to drive inflammatory gene induction (PMID:22269951), and the CUL-4A ubiquitin ligase machinery targets HOXA9 for proteasomal degradation (PMID:14609952). The t(7;11) translocation fuses the NUP98 N-terminus to the HOXA9 homeodomain, generating an aberrant transcription factor whose FG repeats co-opt CBP/p300 and recruit MLL, which is escape from CUL-4A degradation and chromatin targeting via CRM1 drive Hox-locus activation and transformation (PMID:8563753, PMID:9858599, PMID:28210005, PMID:17178874). Beyond hematopoiesis, HOXA9 acts as a tumor suppressor in several solid cancers, modulating BRCA1, TGF-beta2, P-cadherin, and HIF-1alpha-driven glycolysis (PMID:20389018, PMID:22945634, PMID:25023983, PMID:29662084).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1996 High

    Establishing the molecular structure of a recurrent AML translocation revealed that HOXA9 itself is a target of leukemogenic gene fusion.

    Evidence Translocation mapping and transcript cloning in t(7;11) AML patients

    PMID:8563753

    Open questions at the time
    • Did not establish the transforming mechanism of the fusion
    • Fusion protein function unaddressed
  2. 1998 High

    Demonstrating that HOXA9 transforms only in collaboration with MEIS1a and not PBX1b defined cofactor selectivity as the determinant of leukemic transformation.

    Evidence Retroviral overexpression in primary bone marrow and FDC-P1 cells with mouse transplantation

    PMID:9649441

    Open questions at the time
    • Molecular basis of MEIS1a-specific synergy not resolved
    • Direct target genes not yet identified
  3. 1999 High

    Biochemical reconstitution showed HOXA9 assembles trimeric complexes with PBX2 and MEIS1, explaining how cofactors stabilize DNA binding, while parallel work dissected how the NUP98-HOXA9 fusion converts these activities into transformation.

    Evidence EMSA, reciprocal co-IP from myeloid nuclear extracts, immunofluorescence; plus NIH 3T3 transformation and CBP/p300 co-IP with domain mutagenesis

    PMID:10082572 PMID:9858599

    Open questions at the time
    • In vivo target loci of the trimer not mapped
    • How FG-repeat coactivator recruitment alters genome-wide targeting unknown
  4. 2003 High

    A crystal structure plus stability and degradation studies revealed both the structural basis of HOXA9 DNA recognition and that its protein levels are actively controlled by ubiquitin-proteasome turnover.

    Evidence 1.9 A X-ray crystallography with DNA-binding mutagenesis; ubiquitylation assay, proteasome inhibition, CUL-4A RNAi and 32D differentiation

    PMID:12923056 PMID:14609952

    Open questions at the time
    • The E3 substrate-recognition adaptor for CUL-4A not defined
    • Signals triggering degradation unknown
  5. 2004 High

    Identifying PKC phosphorylation of Ser204/Thr205 established a post-translational switch that lowers HOXA9 DNA binding and links it to myeloid differentiation.

    Evidence In vitro kinase assay, site mutagenesis, EMSA, phorbol ester/PKC inhibitor treatment of myeloid cells

    PMID:15082777

    Open questions at the time
    • PKC isoform responsible not specified
    • In vivo relevance during differentiation not directly tested
  6. 2005 High

    Functional target studies extended HOXA9 beyond leukemia, defining it as a master regulator of endothelial maturation and a context-dependent activator of myeloid CYBB that the NUP98 fusion subverts.

    Evidence HoxA9 KO mouse with ischemia/neovascularization assay and target-gene readouts; reporter/EMSA promoter studies of CYBB

    PMID:15681849 PMID:15928198

    Open questions at the time
    • Cofactor logic distinguishing activation vs repression incompletely mapped
    • CYBB regulation single-lab reporter evidence
  7. 2007 High

    Direct ChIP-validated identification of Pim1 as a target connected HOXA9 to suppression of apoptosis via BAD inactivation, providing a survival mechanism for its transforming activity.

    Evidence ChIP, qRT-PCR, Hoxa9-/- cells with Pim1 rescue and BAD phosphorylation readout

    PMID:17327400

    Open questions at the time
    • Cofactor requirements at the Pim1 promoter not defined
    • Other survival targets not enumerated here
  8. 2008 High

    Epigenetic and post-transcriptional studies clarified how HOXA9 expression is maintained (MLL protecting CpG clusters from methylation) and limited (miR-126 targeting the homeobox), while RNAi confirmed its requirement in MLL-rearranged leukemia.

    Evidence MLL ChIP with bisulfite sequencing and Mll-null reconstitution; miR-126 reporter and gain/loss assays; RNAi knockdown with in vivo leukemia model

    PMID:18474618 PMID:18483194 PMID:19056693

    Open questions at the time
    • How MLL excludes the methylation machinery mechanistically unclear
    • miR-126 evidence single-lab
  9. 2010 Medium

    Restoring HOXA9 in breast cancer revealed a tumor-suppressive role mediated through BRCA1, expanding HOXA9 function beyond hematopoiesis into solid-tumor restraint.

    Evidence HOXA9 overexpression/knockdown, xenografts, BRCA1 ectopic rescue epistasis

    PMID:20389018

    Open questions at the time
    • Direct vs indirect regulation of BRCA1 not fully resolved
    • Single-lab finding
  10. 2012 High

    Distinct cofactor and modification studies defined PBX3 as the leukemia-specific TALE partner, PRMT5 as an inflammatory-activating arginine methyltransferase, and TGF-beta2 as a paracrine target driving the tumor microenvironment.

    Evidence shRNA/co-expression leukemogenesis and HXR9 peptide; MS-identified PRMT5 interaction with Arg140 mutagenesis and ChIP; HOXA9-overexpression fibroblast co-culture and xenografts

    PMID:22269951 PMID:22945634 PMID:23264595

    Open questions at the time
    • Why PBX3 differs functionally from PBX1/2 at target loci unclear
    • TGF-beta2 evidence single-lab Medium
  11. 2013 High

    A cluster of studies mapped the upstream regulators (SALL4/MLL, Cdx4/menin, TET1, USF2) and downstream effectors (Bcl-2 survival, JMJD1C-modulated programs, a Cul4a-Geminin ligase activity) that build the HOXA9 regulatory network.

    Evidence ChIP/co-IP for SALL4-MLL and Cdx4-menin at the Hoxa9 locus; TET1 demethylation ChIP/xenografts; inducible HoxA9 with Bcl-2 KO; JMJD1C co-IP and conditional KO LSC assays; Hoxa9-Roc1-Ddb1-Cul4a complex with Geminin ubiquitylation

    PMID:17183676 PMID:23326393 PMID:23716660 PMID:24051379 PMID:24177192 PMID:26878175

    Open questions at the time
    • Geminin-ligase activator role single-lab Medium
    • Integration of multiple upstream activators into a single regulatory logic not established
  12. 2014 High

    Genome-wide co-occupancy with C/EBPalpha and joint repression of Cdkn2a/b established that HOXA9 and C/EBPalpha cooperate broadly to overcome cell-cycle restraint in leukemia.

    Evidence ChIP-seq co-occupancy, loss-of-function mouse leukemia models, proliferation assays

    PMID:24958854

    Open questions at the time
    • Whether C/EBPalpha is recruited by HOXA9 or vice versa not fully resolved here
    • Mechanism of Cdkn2a/b co-repression undefined
  13. 2016 Medium

    Defining CRM1-mediated chromatin recruitment and DACH1 partnership of the fusion and wild-type proteins added new modes of HOXA9/NUP98-HoxA9 chromatin targeting.

    Evidence ChIP-seq with leptomycin B for NUP98-HoxA9; endogenous HOXA9-DACH1 co-IP with reporter comparison

    PMID:22902925 PMID:26740045

    Open questions at the time
    • DACH1 interaction is a single low-confidence Co-IP without functional in vivo validation
    • Mechanism of CRM1-dependent locus selectivity incompletely defined
  14. 2017 High

    Demonstrating that NUP98-HOXA9 requires MLL for chromatin recruitment and leukemogenesis tied the oncogenic fusion mechanistically to the H3K4 methylation machinery, while TWIST1/WDR5 work showed COMPASS-like recruitment also activates the wild-type HOXA9 promoter.

    Evidence Co-IP with FG-repeat domain mapping, MLL conditional KO, ChIP at HOXA locus; TWIST1-WDR5 co-IP and H3K4me3 ChIP-seq at HOXA9 promoter

    PMID:28210005 PMID:28484075

    Open questions at the time
    • Stoichiometry and assembly order of fusion-MLL complex unresolved
    • TWIST1/WDR5 link single-lab Medium
  15. 2018 High

    Defining HOXA9 as a pioneer factor at de novo enhancers that recruits MLL3/MLL4 and co-occupies the genome with STAT5, together with a positive-feedback loop enforcing the HoxA locus and cell-cycle/oncogene targets, established the genome-wide architecture of HOXA9-driven leukemia and revealed solid-tumor metabolic roles.

    Evidence ChIP-seq pioneer assays with MLL3/MLL4 KO; HOXA9-STAT5 ChIP/ATAC-seq with JAK3-mutant leukemia model; inducible ChIP-seq feedback mapping; HOXA9-CRIP2 co-IP/ChIP repressing glycolytic genes

    PMID:29496663 PMID:29662084 PMID:30270123 PMID:30463913

    Open questions at the time
    • How HOXA9 accesses closed chromatin as a pioneer factor not mechanistically defined
    • CRIP2/glycolysis finding single-lab Medium
  16. 2020 High

    Functional screening identified USF2 as a direct upstream activator of HOXA9 in MLL-rearranged leukemia, validated by rescue, completing a transcriptional dependency map.

    Evidence CRISPR screen with HOXA9 reporter, CUT&RUN occupancy, USF2 depletion with Hoxa9 rescue

    PMID:33001025

    Open questions at the time
    • Whether USF2 cooperates with MLL at the HOXA9 promoter not established
    • Role outside MLLr leukemia untested
  17. 2021 Medium

    Identifying Tip60-mediated H2A.Z acetylation and Trib1-modulated super-enhancers refined the epigenetic mechanisms that sustain Hoxa9 expression and downstream oncogenic targets such as Erg.

    Evidence Tip60 ChIP, H2A.Z acetylation assay and conditional KO; Trib1 H3K27Ac ChIP-seq with Erg knockdown and JQ1 treatment

    PMID:32730594 PMID:33967269

    Open questions at the time
    • Both are single-lab Medium-confidence findings
    • Integration with the MLL3/MLL4 enhancer program unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How HOXA9 selects between transactivation and repression at different loci, and how its pioneer activity opens closed chromatin, remain mechanistically undefined.
  • No structural model of HOXA9 engaging nucleosomal/closed chromatin
  • Cofactor and post-translational logic distinguishing activator vs repressor states not unified
  • Substrate spectrum of the proposed Hoxa9-Cul4a ligase activity not broadly mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 3 GO:0140097 catalytic activity, acting on DNA 1
Localization
GO:0005634 nucleus 2 GO:0005654 nucleoplasm 1
Pathway
R-HSA-1643685 Disease 5 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-392499 Metabolism of proteins 3 R-HSA-4839726 Chromatin organization 3 R-HSA-1266738 Developmental Biology 2
Partners
CEBPAJMJD1CMEIS1PBX1PBX2PBX3PRMT5STAT5
Complex memberships
HOXA9-PBX-MEIS1 trimerMLL3/MLL4 (COMPASS-like) complexRoc1-Ddb1-Cul4a ubiquitin ligase

Evidence

Reading pass · 42 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 HOXA9 transforms primary bone marrow cells through selective collaboration with MEIS1a but not PBX1b; co-expression of HOXA9 and MEIS1a induces growth factor-dependent acute myeloid leukemia in mice, while HOXA9+PBX1b fails to transform cells acutely. Retroviral overexpression in primary bone marrow cells, mouse transplantation model, FDC-P1 cell transplantation The EMBO journal High 9649441
1996 The t(7;11)(p15;p15) chromosomal translocation creates an in-frame genomic fusion between HOXA9 and NUP98, generating a chimeric NUP98/HOXA9 transcript containing the NUP98 amino-terminal half fused to the HOXA9 homeodomain. Chromosomal translocation mapping, molecular cloning, transcript analysis in three AML patients Nature genetics High 8563753
1999 NUP98-HOXA9 fusion protein acts as an aberrant transcription factor: the NUP98 FG repeats function as potent transactivation domains by physically interacting with coactivators CBP and p300, while the HOXA9 homeodomain provides DNA-binding and PBX heterodimerization; both activities are required for NIH 3T3 transformation. NIH 3T3 transformation assay, transactivation reporter assays, co-immunoprecipitation of CBP/p300 with FG repeats, domain mutagenesis Molecular and cellular biology High 9858599
1999 HOXA9 forms trimeric complexes with PBX2 and MEIS1 in myeloid cells: MEIS1 enhances HOXA9-PBX complex formation in the absence of DNA, and the three proteins co-immunoprecipitate from myeloid cell nuclear extracts; co-localization occurs in nuclear speckles. EMSA, DNA site selection, co-immunoprecipitation from myeloid cell nuclear extracts, immunofluorescence co-localization Molecular and cellular biology High 10082572
2003 Crystal structure of HoxA9 complexed with Pbx1 and DNA at 1.9 Å resolution reveals that the posterior Hox hexapeptide adopts an altered conformation compared to anterior HOX/PBC structures, providing stronger DNA-binding affinity and altered specificity; residues in the N-terminal arm of the homeodomain are critical for DNA sequence recognition through indirect contacts. X-ray crystallography (1.9 Å), DNA-binding mutagenesis of HoxA9 and HoxB1 Genes & development High 12923056
2003 CUL-4A ubiquitylation machinery controls HOXA9 protein stability by promoting its ubiquitylation and proteasome-dependent degradation; the HOXA9 homeodomain is required for CUL-4A-mediated degradation; interference with CUL-4A biosynthesis alters HOXA9 steady-state levels and impairs granulocyte differentiation of 32D myeloid progenitors. Ubiquitylation assay, proteasome inhibition, RNAi knockdown of CUL-4A, ectopic CUL-4A expression, 32D cell differentiation assay The EMBO journal High 14609952
2004 HOXA9 is phosphorylated by protein kinase C (PKC) on Ser204 and Thr205 within the N-terminal region of the homeodomain; PKC-mediated phosphorylation decreases HOXA9 DNA-binding affinity in vitro and reduces cooperative DNA-binding with PBX; PKC inhibition reduces phorbol ester-induced myeloid differentiation, linking HOXA9 phosphorylation to differentiation regulation. In vitro kinase assay with purified HOXA9, site-directed mutagenesis, EMSA, phorbol ester/PKC inhibitor treatment of PLB985 and HOXA9-immortalized murine marrow cells Molecular and cellular biology High 15082777
2001 HOXA9 binds to a Hox binding site in the osteopontin (OPN) promoter and acts as a transcriptional repressor of OPN; Smad4 physically interacts with HOXA9 (co-immunoprecipitation from cotransfected COS-1 cells) and displaces HOXA9 from its cognate DNA site in response to TGF-β stimulation, thereby derepressing OPN transcription. Gel shift (EMSA) with GST-Smad3, co-immunoprecipitation of FLAG-Smad4 with HA-HOXA9, luciferase reporter transfection assays The Journal of biological chemistry High 11042172
2005 HOXA9 activates transcription of the CYBB gene (encoding gp91Phox) in differentiated myeloid cells via a cis-element in the proximal promoter; this activation requires PBX1 and is inhibited by MEIS1; phosphorylation of conserved homeodomain tyrosines increases HOXA9 binding to the CYBB promoter; the NUP98-HOXA9 fusion has greater binding affinity but is unresponsive to tyrosine phosphorylation and blocks CYBB transcription. Reporter gene assays, EMSA, promoter binding studies, phosphorylation assays, expression in myeloid cells The Journal of biological chemistry Medium 15681849
2005 HDAC activity is required for HoxA9 expression in adult progenitor cells; HoxA9 acts as a master switch to regulate endothelial-committed genes (eNOS, VEGFR2, VE-cadherin) and mediates shear stress-induced endothelial maturation; HoxA9-deficient mice show reduced endothelial progenitor cells and impaired postnatal neovascularization. HDAC inhibitor treatment, HoxA9 overexpression rescue experiments, siRNA knockdown, HoxA9 knockout mouse model with ischemia assay The Journal of experimental medicine High 15928198
2007 Pim1 kinase is a direct transcriptional target of HOXA9; HOXA9 protein binds the Pim1 promoter and induces Pim1 mRNA and protein in hematopoietic cells; Pim1 induction by HOXA9 increases phosphorylation and inactivation of pro-apoptotic BAD; Hoxa9-/- cells show increased apoptosis and decreased proliferation that are rescued by Pim1 reintroduction. Chromatin immunoprecipitation (ChIP), quantitative RT-PCR, Western blot, Hoxa9-/- mouse cells, Pim1 rescue experiments Blood High 17327400
2007 HOXA9 inhibits NF-κB-dependent activation of endothelial cells; HOXA9 overexpression inhibits induction of ICAM-1, VCAM-1, and E-selectin in response to pro-inflammatory cytokines by interfering with NF-κB DNA binding (but not its transactivation capacity or nuclear localization). Luciferase reporter assays with NF-κB-dependent promoters, EMSA for NF-κB DNA binding, HOXA9 overexpression in endothelial cells Atherosclerosis Medium 17586512
2007 NF-κB activation is required for HOXA9 transcriptional downregulation during endothelial cell activation; HOXA9 positively autoregulates its own expression requiring both its DNA-binding and transactivation domains. HOXA9 promoter deletion analysis, reporter assays in endothelial cells and NF-κB knockout cells Gene Medium 18068911
2008 MLL binds to specific CpG clusters within the Hoxa9 locus and protects them from DNA methylation, thereby maintaining Hoxa9 transcript expression; shRNA knockdown of MLL reverses methylation protection at these CpG clusters; reconstituting MLL expression in Mll-null cells reverses DNA methylation, demonstrating a dominant protective effect. ChIP of MLL at Hoxa9 locus, bisulfite sequencing of CpG methylation, shRNA knockdown of Mll, Mll-null cell reconstitution Proceedings of the National Academy of Sciences of the United States of America High 18483194
2008 miR-126 targets highly conserved sites within the HOXA9 homeobox coding sequence; forced expression of miR-126 downregulates HOXA9 protein and causes loss of biological activity in HOXA9-immortalized bone marrow cells; inhibition of endogenous miR-126 increases HOXA9 protein. Forced miRNA expression, luciferase reporter targeting assays, Western blot for HOXA9 protein, miR-126 inhibitor in F9 cells Molecular and cellular biology Medium 18474618
2008 HOXA9 suppression in MLL-rearranged leukemia cells induces proliferation arrest and apoptosis and co-downregulates HOXA10, MEIS1, PBX3, and MEF2C; HOXA9 depletion reduces leukemia burden in vivo in mice transplanted with t(4;11) SEMK2 cells. RNA interference knockdown, gene expression profiling, apoptosis assays, in vivo mouse leukemia model Blood High 19056693
2010 HOXA9 directly modulates BRCA1 expression to restrict breast tumor behavior; restoring HOXA9 expression represses growth and survival of breast cancer cells in culture and xenograft models; wild-type BRCA1 phenocopies HOXA9 tumor suppressor function, and reducing BRCA1 inhibits HOXA9 anti-tumor activity. HOXA9 overexpression and knockdown, xenograft mouse model, molecular correlation studies, BRCA1 ectopic expression rescue The Journal of clinical investigation Medium 20389018
2012 PRMT5 is a TNF-α-dependent binding partner of HOXA9 (identified by mass spectrometry); PRMT5 induces symmetric dimethylation of Arg140 on HOXA9, which is essential for HOXA9-dependent E-selectin induction; PRMT5 is recruited to the E-selectin promoter following HOXA9 binding; siRNA depletion of PRMT5 abrogates stimulus-dependent HOXA9 methylation and E-selectin/VCAM-1 induction. Mass spectrometry protein identification, Co-IP, siRNA depletion, ChIP, site-directed mutagenesis of Arg140 Molecular and cellular biology High 22269951
2012 PBX3, but not PBX1 or PBX2, is a critical cofactor of HOXA9 in leukemogenesis; PBX3 depletion significantly inhibits MLL-fusion-mediated cell transformation; co-expressed PBX3 synergizes with HOXA9 in promoting cell transformation in vitro and leukemogenesis in vivo; a peptide (HXR9) disrupting HOX-PBX interactions selectively kills leukemic cells overexpressing HOXA/PBX3. shRNA depletion of PBX3, retroviral co-expression of HOXA9+PBX3, in vivo leukemogenesis mouse model, HXR9 peptide treatment assay Blood High 23264595
2012 HOXA9 expression in ovarian cancer cells induces normal peritoneal fibroblasts to acquire cancer-associated fibroblast (CAF) markers; these effects are due substantially to HOXA9 transcriptional activation of TGF-β2, which acts in a paracrine manner to induce CXCL12, IL-6, and VEGF-A in fibroblasts/MSCs. HOXA9 overexpression in EOC cells, fibroblast co-culture, xenograft mouse model, TGF-β2 promoter analysis The Journal of clinical investigation Medium 22945634
2013 HMGA2 depletion induces TET1 expression; TET1 binds and demethylates its own promoter and the HOXA gene promoters (including HOXA9) to enhance HOXA gene expression; both TET1 and HOXA9 suppress breast tumor growth and metastasis in mouse xenografts. ChIP, bisulfite sequencing/methylation analysis, xenograft mouse models, HMGA2 depletion Proceedings of the National Academy of Sciences of the United States of America Medium 23716660
2013 JMJD1C directly interacts with HOXA9 and modulates a HOXA9-controlled gene-expression program; loss of JMJD1C substantially decreases leukemia stem cell (LSC) frequency and causes differentiation of MLL-AF9- and HOXA9-driven leukemias, while having only minor effects on normal hematopoietic stem cell self-renewal. Co-immunoprecipitation (JMJD1C-HOXA9 interaction), conditional knockout mouse model, in vivo shRNA screen, LSC frequency assay The Journal of clinical investigation High 26878175
2013 HoxA9 maintains Bcl-2 expression in hematopoietic cells; maintenance of HoxA9 overexpression is required for continued cell survival even in the presence of growth factors; hematopoietic cells lacking Bcl-2 are not immortalized by HoxA9 in vitro; deletion of Bcl-2 delays onset and reduces severity of HoxA9/Meis1 and MLL-AF9 leukemias. Inducible HoxA9 system (4-OHT-regulated), Bcl-2 knockout cells, in vivo leukemia mouse model with Bcl-2 deletion Oncotarget High 24177192
2013 SALL4 binds the HOXA9 promoter, and SALL4 overexpression leads to enhanced binding of histone activation markers at the HOXA9 promoter and increased HOXA9 expression; SALL4 co-occupies the HOXA9 promoter with MLL in AML cells (co-immunoprecipitation between SALL4 and MLL), suggesting a SALL4/MLL pathway controlling HOXA9 expression. ChIP of SALL4 at HOXA9 promoter, co-immunoprecipitation of SALL4 and MLL, histone modification ChIP, shRNA knockdown in leukemic cells The Journal of clinical investigation Medium 24051379
2014 C/EBPα is a critical collaborator required for Hoxa9/Meis1-mediated leukemogenesis; C/EBPα loss greatly improves survival in primary and secondary murine Hoxa9/Meis1 leukemia models; >50% of Hoxa9 genome-wide binding sites are co-occupied by C/EBPα; Hoxa9 and C/EBPα co-repress the Cdkn2a/b locus to overcome G1 cell cycle block. ChIP-seq (genome-wide co-occupancy), loss-of-function mouse models, cell proliferation assays Proceedings of the National Academy of Sciences of the United States of America High 24958854
2006 Cdx4 and menin bind the same regulatory region of the Hoxa9 locus in vivo and co-activate Hoxa9 reporter gene expression; ablation of menin abrogates Cdx4 chromatin access and reduces both active and repressive histone H3 modifications at the Hoxa9 locus; H3K4me3 levels at Hoxa9 correlate with expression levels. ChIP of Cdx4 and menin at Hoxa9 locus, reporter gene assays, menin ablation with ChIP readout for histone marks PloS one Medium 17183676
2013 HOXA9 binds the CDH3 (P-cadherin) promoter, induces CDH3 expression, and promotes aggregation, anoikis resistance, peritoneal attachment, and migration of ovarian cancer cells; inhibiting P-cadherin abrogates HOXA9-stimulated effects, and reconstituting P-cadherin in HOXA9-inhibited cells restores these effects. ChIP of HOXA9 at CDH3 promoter, shRNA knockdown, P-cadherin overexpression/inhibition rescue, in vivo xenograft peritoneal model Molecular cancer Medium 25023983
2016 Chromatin-prebound CRM1 recruits NUP98-HoxA9 to Hox cluster regions; NUP98-HoxA9 forms nuclear aggregates associated with facultative heterochromatin and selectively induces Hox cluster gene expression; leptomycin B (CRM1 inhibitor) disassembles NUP98-HoxA9 nuclear dots and abolishes Hox gene activation. Genome-wide ChIP-seq of NUP98-HoxA9, leptomycin B treatment, stable expression in mouse ES cells eLife Medium 26740045
2017 MLL is essential for NUP98-HOXA9-induced leukemia; NUP98-HOXA9 interacts with MLL via the second FG repeat domain of NUP98; in the absence of MLL, NUP98-HOXA9-induced cell immortalization and leukemogenesis are severely inhibited; MLL is required for NUP98-HOXA9 recruitment to the HOXA locus and HOXA gene expression. Co-immunoprecipitation (NUP98-HOXA9 with MLL), FG repeat domain mutagenesis, MLL conditional knockout in leukemia model, ChIP of NUP98-HOXA9 at HOXA locus Leukemia High 28210005
2018 HOXA9 functions as a pioneer factor at de novo enhancers during leukemogenesis, recruits C/EBPα and the MLL3/MLL4 complex; genetic deletion of MLL3/MLL4 blocks H3K4 methylation at de novo enhancers and inhibits HOXA9/MEIS1-mediated leukemogenesis in vivo. ChIP-seq (HOXA9 enhancer occupancy), MLL3/MLL4 conditional knockout, H3K4me1/H3K27ac profiling, in vivo leukemogenesis assay Cancer cell High 30270123
2018 HOXA9 and STAT5 have genome-wide co-occupancy; co-expression of HOXA9 and mutant JAK3 leads to enhanced STAT5 transcriptional activity and ectopic activation of FOS/JUN (AP1), accelerating leukemia development from multipotent or lymphoid-committed progenitors. ChIP-seq, ATAC-seq, RNA-seq in primary mouse cells, mouse leukemia model with JAK3 mutant + HOXA9 Cancer discovery High 29496663
2018 HOXA9 inhibits HIF-1α-mediated glycolysis in cutaneous squamous cell carcinoma; mechanistic studies show HOXA9-CRIP2 interaction at glycolytic gene promoters impedes HIF-1α binding and represses HK2, GLUT1, and PDK1 expression in trans. Co-immunoprecipitation (HOXA9-CRIP2 interaction), ChIP at glycolytic gene promoters, in vitro and xenograft tumor models, HOXA9 overexpression/knockdown Nature communications Medium 29662084
2018 HoxA9 drives a positive-feedback loop that enforces expression of the complete HoxA locus and controls oncogenic transcription factors Myc and Myb; HoxA9 directly induces cell cycle regulators Cdk6 and CyclinD1, as well as telomerase; HoxA9 is a substrate for granule proteases (which had confounded prior ChIP-seq in primary cells). ChIP-seq in protease knockout primary murine cells and human AML line, inducible HoxA9 system, genome-wide enhancer/promoter mapping Blood advances Medium 30463913
2019 The human HOXA9 protein interacts with TALE cofactors PBX1 and MEIS1 through a combination of the hexapeptide (HX) motif and two paralog-specific residues of the HOXA9 homeodomain; this interaction is context-independent across different DNA-binding sites and cell lines. Bimolecular Fluorescence Complementation (BiFC) in multiple cell lines, in vitro binding assays on different DNA sites, mutagenesis of HX motif and HD residues Scientific reports Medium 30952900
2013 Hoxa9 forms a complex with Roc1-Ddb1-Cul4a ubiquitin ligase and functions as an E3 ubiquitin ligase activator for Geminin; Hoxa9 overexpression or siRNA knockdown respectively down-regulates or up-regulates Geminin protein in hematopoietic cells; Hoxa9-induced repopulating and clonogenic activities are suppressed by Geminin supertransduction. Co-immunoprecipitation (Hoxa9-Roc1-Ddb1-Cul4a complex), ubiquitylation assay for Geminin, retroviral Hoxa9 transduction, siRNA knockdown, Geminin rescue experiment PloS one Medium 23326393
2021 Trib1 modulates Hoxa9-associated super-enhancers; Trib1 overexpression increases H3K27Ac signals at super-enhancers of Erg, Spns2, Rgl1, and Pik3cd loci, and this is mostly achieved via Trib1-mediated degradation of C/EBPα p42; Erg is a critical downstream target of the Trib1/Hoxa9 axis. ChIP-seq for H3K27Ac, Erg knockdown, BRD4 inhibitor (JQ1) treatment in vitro and in vivo, Trib1 overexpression in AML cells Blood Medium 32730594
2020 USF2 directly occupies the HOXA9 promoter in MLL-rearranged leukemia cells (by CUT&RUN analysis) and controls HOXA9 expression; USF2 depletion significantly down-regulates HOXA9 expression and impairs MLLr leukemia cell proliferation; ectopic Hoxa9 expression rescues impaired proliferation upon USF2 loss. CRISPR/Cas9 screen with HOXA9-mCherry reporter, CUT&RUN (chromatin occupancy), USF2 depletion/rescue experiments eLife High 33001025
2021 Tip60 histone acetyltransferase is recruited by MLL-AF10 and MLL-ENL fusions to the Hoxa9 locus, where it acetylates H2A.Z to promote Hoxa9 gene expression; conditional deletion of Tip60 prevents development of MLL-AF10 and MLL-ENL leukemia. ChIP of Tip60 at Hoxa9 locus, H2A.Z acetylation assay, conditional Tip60 knockout in leukemia mouse model Leukemia Medium 33967269
2006 The NUP98-HOXA9 fusion protein is protected from CUL-4A-mediated ubiquitination and proteasome-dependent degradation (unlike wild-type HOXA9), contributing to protein stabilization; co-expression of C/EBPα with NUP98-HOXA9 reverses the enhanced proliferation of transduced CD34+ cells. Ubiquitination assay comparing NUP98-HOXA9 vs HOXA9, proteasome inhibition, C/EBPα co-expression rescue in CD34+ cells Cancer research Medium 17178874
2019 HOXA9 transcriptionally regulates RELA (the p65 subunit of NF-κB) in cutaneous SCC; loss of HOXA9 upregulates RELA and thus enhances the NF-κB pathway, which in turn transcriptionally promotes anti-apoptotic BCL-XL and autophagic genes ATG1, ATG3, and ATG12. RNA-seq after HOXA9 knockdown, KEGG pathway analysis, reporter assays, ChIP/promoter analysis for RELA Cells Low 31683603
2017 TWIST1 forms a complex with WDR5 and lncRNA Hottip, which are members of the MLL/COMPASS-like H3K4 methylase complex; TWIST1 overexpression leads to co-enrichment of TWIST1 and WDR5 at the HOXA9 promoter with increased H3K4me3, dependent on WDR5. Co-immunoprecipitation (TWIST1-WDR5 complex), ChIP-seq for H3K4me3 at HOXA9 promoter, WDR5 knockdown Cancer research Medium 28484075
2016 DACH1 forms an endogenous complex with HOXA9 (mediated by the DACH1 carboxyl terminus) in t(9;11) leukemia cells; DACH1 has stronger transcription-promoting activity with HOXA9 than does PBX2 with HOXA9. Co-immunoprecipitation of endogenous HOXA9-DACH1 complex, domain mapping (DACH1 C-terminus), quantitative reporter assay comparison Biochemical and biophysical research communications Low 22902925

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1998 Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. The EMBO journal 545 9649441
1996 Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nature genetics 440 8563753
2002 Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 287 11756161
1999 CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Molecular and cellular biology 283 9858599
2008 HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 273 19056693
2004 Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Molecular and cellular biology 273 14701735
2013 HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 230 23716660
1999 HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Molecular and cellular biology 206 10082572
1999 Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 190 10602420
2003 Structure of HoxA9 and Pbx1 bound to DNA: Hox hexapeptide and DNA recognition anterior to posterior. Genes & development 168 12923056
2015 Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene 163 26028034
2005 Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. The Journal of experimental medicine 142 15928198
2012 miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nature communications 130 22353710
2018 HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development. Nature communications 119 29662084
2012 HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. The Journal of clinical investigation 118 22945634
2012 PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood 118 23264595
2008 MicroRNA-126 regulates HOXA9 by binding to the homeobox. Molecular and cellular biology 116 18474618
2018 HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer cell 115 30270123
2017 TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer research 102 28484075
2002 Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene 102 12082612
2016 Deregulation of the HOXA9/MEIS1 axis in acute leukemia. Current opinion in hematology 100 27258906
2010 HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. The Journal of clinical investigation 100 20389018
2014 HOXA9 promotes hematopoietic commitment of human embryonic stem cells. Blood 90 25185710
2020 CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Cancer cell international 83 32655321
2018 HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer discovery 80 29496663
2008 MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proceedings of the National Academy of Sciences of the United States of America 79 18483194
2007 Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. Journal of hypertension 78 17885552
2012 HOXA9 methylation by PRMT5 is essential for endothelial cell expression of leukocyte adhesion molecules. Molecular and cellular biology 73 22269951
2016 MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. The Journal of clinical investigation 72 26878175
2001 Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. The Journal of biological chemistry 72 11042172
2014 Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 70 24486589
2014 C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America 70 24958854
2016 Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of Hox cluster genes. eLife 67 26740045
2005 Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells. Stem cells (Dayton, Ohio) 67 15849172
2003 The oncogene Nup98-HOXA9 induces gene transcription in myeloid cells. The Journal of biological chemistry 66 14561764
2003 CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein. The EMBO journal 64 14609952
2006 Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer research 63 17178874
2007 Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 59 17327400
2005 HOXA9 activates transcription of the gene encoding gp91Phox during myeloid differentiation. The Journal of biological chemistry 59 15681849
2014 Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. The American journal of pathology 57 24332016
2020 Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer. International journal of cancer 55 32191343
2017 Overexpression of HOXA4 and HOXA9 genes promotes self-renewal and contributes to colon cancer stem cell overpopulation. Journal of cellular physiology 55 28464221
2003 Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leukemia & lymphoma 55 14738146
2019 Circular RNA SMARCA5 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by miR-19b-3p/HOXA9 axis. OncoTargets and therapy 51 31564891
2011 Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clinical chemistry and laboratory medicine 50 21480815
2015 IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia. Cancer research 49 25795706
2015 Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer. PloS one 48 26332997
2019 Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia. Cancers 46 31213012
2021 Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9. Blood 43 32730594
2015 Key pathways regulated by HoxA9,10,11/HoxD9,10,11 during limb development. BMC developmental biology 43 26186931
2004 Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation. Molecular and cellular biology 43 15082777
2013 HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget 42 24177192
2011 RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis. Cell cycle (Georgetown, Tex.) 42 21467841
2013 A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. The Journal of clinical investigation 41 24051379
2019 JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia 39 30622285
2021 ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9. Journal of cellular and molecular medicine 38 34850551
2018 HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes. Blood advances 38 30463913
2007 Homeobox gene HOXA9 inhibits nuclear factor-kappa B dependent activation of endothelium. Atherosclerosis 38 17586512
2020 Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clinical cancer research : an official journal of the American Association for Cancer Research 35 32820015
2019 LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway. Journal of cellular biochemistry 35 30838699
2018 Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival. Theranostics 35 30214626
2010 Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines. Molecular cancer 35 20565746
2021 Molecular regulators of HOXA9 in acute myeloid leukemia. The FEBS journal 34 34743404
2014 Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas. Clinical chemistry and laboratory medicine 34 24681432
2008 HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia. Leukemia 34 18337761
2020 Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen. eLife 33 33001025
2007 Differential regulation of HOXA9 expression by nuclear factor kappa B (NF-kappaB) and HOXA9. Gene 33 18068911
2022 False-positive IRESes from Hoxa9 and other genes resulting from errors in mammalian 5' UTR annotations. Proceedings of the National Academy of Sciences of the United States of America 32 36037358
2017 RUNX3 inhibits the proliferation and metastasis of gastric cancer through regulating miR-182/HOXA9. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 32 29054094
2014 HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin. Molecular cancer 32 25023983
2007 Hoxa9/hoxb3/hoxb4 compound null mice display severe hematopoietic defects. Experimental hematology 32 17761289
2019 HOXA9 Transcriptionally Promotes Apoptosis and Represses Autophagy by Targeting NF-κB in Cutaneous Squamous Cell Carcinoma. Cells 31 31683603
2017 MLL is essential for NUP98-HOXA9-induced leukemia. Leukemia 31 28210005
2020 HIF-1α or HOTTIP/CTCF Promotes Head and Neck Squamous Cell Carcinoma Progression and Drug Resistance by Targeting HOXA9. Molecular therapy. Nucleic acids 30 32169804
2019 Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model. Journal of medicinal chemistry 28 30645099
2006 Cdx4 and menin co-regulate Hoxa9 expression in hematopoietic cells. PloS one 28 17183676
2021 HOXA9-induced chemerin signals through CMKLR1/AMPK/TXNIP/NLRP3 pathway to induce pyroptosis of trophoblasts and aggravate preeclampsia. Experimental cell research 27 34461109
2019 miR-652 Promotes Proliferation and Migration of Uveal Melanoma Cells by Targeting HOXA9. Medical science monitor : international medical journal of experimental and clinical research 27 31740654
2013 Hoxa9 and Flt3 signaling synergistically regulate an early checkpoint in lymphopoiesis. Journal of immunology (Baltimore, Md. : 1950) 27 23772038
2017 HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas. Scientific reports 25 28515451
2013 Role of HOXA9 and VEZF1 in endothelial biology. Journal of vascular research 25 23921720
2022 Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential. Cancer cell international 24 36376832
2021 MicroRNA-638 inhibits the progression of breast cancer through targeting HOXA9 and suppressing Wnt/β-cadherin pathway. World journal of surgical oncology 24 34416888
2020 MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip. BMC medical genomics 24 31906958
2020 miR-647 inhibits glioma cell proliferation, colony formation and invasion by regulating HOXA9. The journal of gene medicine 23 31881106
2024 Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML. Blood 22 38579286
2023 DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax. Theranostics 22 36593968
2021 lncRNA MIR503HG inhibits cell proliferation and promotes apoptosis in TNBC cells via the miR-224-5p/HOXA9 axis. Molecular therapy oncolytics 21 33869743
2019 The human HOXA9 protein uses paralog-specific residues of the homeodomain to interact with TALE-class cofactors. Scientific reports 21 30952900
2013 Hoxa9 transduction induces hematopoietic stem and progenitor cell activity through direct down-regulation of geminin protein. PloS one 21 23326393
2017 Aberrant Expression of lncRNA ( HOXA11-AS1) and Homeobox A ( HOXA9, HOXA10, HOXA11, and HOXA13) Genes in Infertile Women With Endometriosis. Reproductive sciences (Thousand Oaks, Calif.) 20 29017417
2007 Transcriptional complexity of the HOXA9 locus. Blood cells, molecules & diseases 20 17916434
2019 LncRNA PEG10 aggravates cardiac hypertrophy through regulating HOXA9. European review for medical and pharmacological sciences 19 31389601
2017 Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncology letters 19 29435001
2022 HOXA9 Overexpression Contributes to Stem Cell Overpopulation That Drives Development and Growth of Colorectal Cancer. International journal of molecular sciences 18 35743243
2019 The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma. Journal of clinical laboratory analysis 18 30843252
2013 Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. Cancer chemotherapy and pharmacology 18 24141373
2012 Regulation of HOXA9 activity by predominant expression of DACH1 against C/EBPα and GATA-1 in myeloid leukemia with MLL-AF9. Biochemical and biophysical research communications 17 22902925
2022 Long non-coding RNA PCED1B-AS1 promotes the proliferation of colorectal adenocarcinoma through regulating the miR-633/HOXA9 axis. Bioengineered 16 35176937
2021 Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia. Leukemia 16 33967269

Missed literature

Know a paper Affinage missed for HOXA9? Flag it for the maintainers and the community.

No submissions yet.